US2006099633A1PendingUtilityA1

Human FcgammaRIIB gene polymorphisms for assessing development of systemic lupus erythematosus and compositions for use thereof

Assignee: NEW YORK SOC FOR THE RUPTUREDPriority: Feb 26, 2002Filed: Dec 16, 2005Published: May 11, 2006
Est. expiryFeb 26, 2022(expired)· nominal 20-yr term from priority
Inventors:Luminita Pricop
C12Q 2600/156C12Q 1/6883
43
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

The present invention provides methods for predicting the likelihood of development of systemic lupus erythematosus (SLE) in an individual, which comprise determining the sequence at one or more polymorphic positions within the human genes encoding FcγRIIB. The invention also provides isolated nucleic acids encoding FcγRIIB polymorphisms, nucleic acid probes that hybridize to polymorphic positions and kits for the prediction of SLE status.

Claims

exact text as granted — not AI-modified
1 . An isolated nucleic acid derived from the gene encoding human FcγRIIB, wherein the nucleic acid comprises polymorphic position −385 in the promoter region.  
     
     
         2 . A nucleic acid as defined in  claim 1 , wherein the sequence at the polymorphic position in the promoter region is −385C.  
     
     
         3 . An isolated nucleic acid which hybridizes under stringent conditions to a nucleic acid as defined in  claim 2 .  
     
     
         4 . An isolated nucleic acid derived from the gene encoding human FcγRIIB, wherein the nucleic acid comprises polymorphic position −119 in the promoter region.  
     
     
         5 . A nucleic acid as defined in  claim 4 , wherein the sequence at the polymorphic position in the promoter region is −119A.  
     
     
         6 . An isolated nucleic acid which hybridizes under stringent conditions to a nucleic acid as defined in  claim 5 .  
     
     
         7 . An isolated nucleic acid derived from the gene encoding human FcγRIIB, wherein the nucleic acid comprises polymorphic positions −385 and −119 in the promoter region.  
     
     
         8 . A nucleic acid as defined in  claim 7 , wherein the sequences at the polymorphic position in the promoter region are −385C and −119A.  
     
     
         9 . An isolated nucleic acid which hybridizes under stringent conditions to a nucleic acid as defined in  claim 8 .  
     
     
         10 . A kit for assessing the susceptibility of an individual to developing systemic lupus erythematosus comprising sequence determination primers and sequence determination reagents wherein said primers hybridize to the polymorphic positions in the human FcγRIIB gene, wherein the polymorphic positions are −385 and −119 in the promoter region.  
     
     
         11 . A kit for assessing the susceptibility of an individual to developing systemic lupus erythematosus comprising sequence determination primers and sequence determination reagents wherein said primers hybridize to a polymorphic position in the human FcγRIIB gene, wherein the polymorphic positions is −385 in the promoter region.  
     
     
         12 . A kit for assessing the susceptibility of an individual to developing systemic lupus erythematosus comprising sequence determination primers and sequence determination reagents wherein said primers hybridize to a polymorphic position in the human FcγRIIB gene, wherein the polymorphic position is −119 in the promoter region.

Join the waitlist — get patent alerts

Track US2006099633A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.